Product Information
DORZOLAMIDE HCL 2% EYE DROPS is a generic product labeled by Bausch & Lomb Incorporated, priced at $0.8348 per ML under NDC 24208048510. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Jun 25, 2009. Its Orange Book therapeutic-equivalence code is AT.
Strength
20 mg/mL
Manufacturer
Bausch & Lomb IncorporatedNDC
24208048510
Classification
Generic
Dosage Form
SOLUTION/ DROPS
Route
OPHTHALMIC
Effective Date
9/23/2026
Active Ingredients
DORZOLAMIDE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090143FDA Approved
6/25/2009
TE Code
AT
On Market Since
6/25/2009
Pharmacological Classes
Price Statistics
The NADAC for DORZOLAMIDE HCL 2% EYE DROPS has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 46.2%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.8348 per ML |
|---|---|
| All-time high | $1.8762 (May 13, 2020) |
| All-time low | $0.8212 (Jul 22, 2026) |
| 52-week high | $0.9950 |
| 52-week low | $0.8212 |
| Median price | $1.3411 |
| Average price | $1.3382 |
| Largest weekly change | +42.1% (Sep 18, 2024) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Dorzolamide HCl market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Bausch & Lomb Incorporated manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
Dorzolamide HCl market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Carbonic Anhydrase Inhibitor class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DORZOLAMIDE HCL 2% EYE DROPS?
The current National Average Drug Acquisition Cost (NADAC) for DORZOLAMIDE HCL 2% EYE DROPS, manufactured by Bausch & Lomb Incorporated, is $0.8348 per ML (NDC 24208048510), effective Sep 30, 2026.
How has the price of DORZOLAMIDE HCL 2% EYE DROPS changed over time?
Over the history we have for it, the NADAC for DORZOLAMIDE HCL 2% EYE DROPS has declined 46.2%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for DORZOLAMIDE HCL 2% EYE DROPS?
Since Nov 28, 2013, the NADAC for DORZOLAMIDE HCL 2% EYE DROPS has ranged from a low of $0.8212 (Jul 22, 2026) to a high of $1.8762 (May 13, 2020), with a median of $1.3411 per ML.
Are there cheaper alternatives to DORZOLAMIDE HCL 2% EYE DROPS?
No other NADAC-published product currently shares the active ingredient and strength of DORZOLAMIDE HCL 2% EYE DROPS in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DORZOLAMIDE HCL 2% EYE DROPS?
DORZOLAMIDE HCL 2% EYE DROPS (NDC 24208048510) is labeled by Bausch & Lomb Incorporated, and CMS classifies it as a generic product.